Cost-effectiveness evidence for the introduction of a vaccine case study: Georgia – PCV

KEY FINDINGS

A cost-effectiveness study of Pneumococcal Conjugate Vaccine (PCV) introduction in Georgia produced the following key findings.

• PCV introduction in Georgia is predicted to:
• prevent 4 deaths and 717 cases of acute otitis media per year;
• prevent 533 cases of pneumonia per year;
• result in treatment cost savings of US$ 2.14 million;
• have a net cost of US$ 2.3 million;
• Introduction of PCV10 vaccine in Georgia was estimated to be cost-effective based on WHO criteria2 even in the worst-case scenario tested.